CAS: 18826-29-4; 5,12-Bis(Phenylethynyl)Tetracene

上下游产品

CAS号1090-13-7 5,12-萘并萘醌 | CAS号536-74-3 苯乙炔 | CAS号31559-43-0 5,12-dihydro-5,... | CAS号4440-01-1 苯乙酰锂

专利信息

专利号:US-2018150597-A1
优先权日:2016-11-29
标题 :Method for optimal design of polynucleotides sequences for analysis of specific events in any genetic region of interest
发明人：BERTHOUMIEUX SARA; FOURNE YANNICK; KOMATSU JUN; FER FREDERIC; BENSIMON AARON
权利人:GENOMIC VISION SA
摘要:Methods including in-silico steps for design and synthesis of Genomic Morse Code (“GMCâ€?) probes including design of combinations of polynucleotide sequences and labelling colors for analysis of large rearrangements in targeted genetic regions as well as allele characterization of complex regions and localization of events such as replication, DNA reparation or epigenetics in particular regions. Color-encoded sets of probes that produce characteristic or unique color patterns when painted on a target nucleic acid sequence. Methods for using color-encoded sets of probes.

专利号:US-9125942-B2
优先权日:2010-01-19
标题 :Paramagnetic metal-nanodiamond conjugates
发明人：MANUS LISA M; MASTARONE DANIEL J; HO DEAN; MEADE THOMAS J
权利人:MANUS LISA M; MASTARONE DANIEL J; HO DEAN; MEADE THOMAS J; UNIV NORTHWESTERN
摘要:The present invention provides compositions and methods for the synthesis of conjugates of paramagnetic metal ions and nanodiamonds, and uses thereof. In particular, the present invention provides synthesis of paramagnetic metal-nanodiamond conjugates and methods using such compositions as molecular imaging probes.

专利号:WO-2012016973-A1
优先权日:2010-08-02
标 题:Invention related to contact allergens
发明人：SCHMIDT MARC; GOEBELER MATTHIAS; BADRINARAYANAN RAGHAVAN
权利人:TRANSMIT GMBH; SCHMIDT MARC; GOEBELER MATTHIAS; BADRINARAYANAN RAGHAVAN
摘要:The problem of the underlying invention is to foresee a new method and a new class of substances to treat and or reduce hypersensivity (CHS) with mammals, especially humans to nickel, especially Ni 2+ . Surprisingly it was found, that the site-specific h TLR4 inhibition as potential strategy for therapeutic intervention without affecting vital immune responses. Here we demonstrate that Ni 2+ induces an inflammatory response via direct activation of human Toll-like receptor 4 (hTLR4). Remarkably, Ni 2+ induces TLR4 activation is species-specific since mouse TLR4 (mTLR4) is incapable to generate this response. Studies with mutant TLR4 proteins revealed a requirement of the non-conserved histidines 456 and 458 of h TLR4 for activation by Ni 2+ but not by the natural ligand LPS. Accordingly, transgenic h TLR4 expression in Tlr4 -deficient mice allowed efficient sensitization to Ni 2+ and elicitation of CHS. Allergies to nickel (Ni 2+) are the most frequent cause of contact hypersensitivity (CHS) in industrialized countries. Both a T lymphocyte-specific signal and a proinflammatory signal are required for efficient CHS development. Here we demonstrate that Ni 2+ induces an inflammatory response via direct activation of human Toll-like receptor 4 (hTLR4). Remarkably, Ni 2+ induced TLR4 activation is species-specific since mouse TLR4 (m TLR4) is incapable to generate this response. Studies with mutant TLR4 proteins revealed a requirement of the non-conserved histidines 456 and 458 of h TLR4 for activation by Ni2+ but not by the natural ligand LPS. Accordingly, transgenic h TLR4 expression in Tlr4 -deficient mice allowed efficient sensitization to Ni 2+ and elicitation of CHS. Our data implicate site-specific h TLR4 inhibition as potential strategy for therapeutic intervention without affecting vital immune responses. Furthermore it is shown that hypersensitivity-related inflammatory response via direct activation of human Toll-like receptor 4 (h TLR4) is not only induced by nickel but also by cobalt (Co 2+ ). Moreover, the invention surprisingly describes synthesis of truncated h TLR4 molecules (s-h TLR4) missing the transmembrane domain and the C-terminal part of the protein that are applicable in a method for identification of substances to treat and or reduce hypersensitivity (CHS) or sepsis with mammals by inhibition of h TLR4 activation.

专利号:CN-119638694-A
优先权日:2018-11-16
标 题 :Improved synthesis of key intermediates for KRAS G12C inhibitor compounds

专利号:CN-113015724-B
优先权日:2018-11-16
标题 :Improved synthesis of key intermediates for KRAS G12C inhibitor compounds

专利号:CN-119638693-A
优先权日:2018-11-16
标 题 :Improved synthesis of key intermediates for KRAS G12C inhibitor compounds